SR9009 (Stenabolic)
A REV-ERB agonist research compound with significant off-target effects that is not FDA-approved.
Medications & hormones
Research records
Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.
Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.
SR9009 (Stenabolic)
A REV-ERB agonist research compound with significant off-target effects that is not FDA-approved.
Evidence category: Preclinical. This describes the source category, not approval or certainty.
Regulatory statement in source: Not separately recorded; do not infer approval from the evidence category.
SR9009 (Stenabolic) is a synthetic REV-ERBα/REV-ERBβ agonist used as a research tool for circadian rhythm regulation, metabolism, and mitochondrial biogenesis. It activates REV-ERB signaling to regulate circadian clock genes and metabolic pathways. Important limitation: SR9009 is 100-fold more active toward LXRα than REV-ERBs, suggesting observed effects may derive from off-target activity.
Benefits reported in the imported source
- REV-ERB agonism in preclinical models; effects on circadian rhythm and metabolism
Risks and limits
- Not FDA-approved; research use only
- Significant off-target LXRα activity (100-fold over REV-ERB activity)
- Effects may not be due to intended REV-ERB mechanism
- No human safety or efficacy data
Source bottom line: Research tool only with major off-target activity; preclinical effects may not reflect intended mechanism.
Uncertainty: Reference information only. Not medical advice.
Study protocols — reports, not instructions
No study protocol recorded in this snapshot. This does not establish that no study exists.
Community and practice descriptions
Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.
Unverified imported account — SR-9009 Protocol Guide
An imported authored paraphrase, not a quotation or a recommended protocol.
Review: unverified historical account. The imported wording is preserved for attribution; its full clinical, dosing, efficacy or consensus claims have not been independently established. Unvalidated source account; no validated human dosing population or animal-to-human equivalence is inferred.
Imported wording: A protocol documented on Path To Peptides describes 20-30 mg administered orally in split doses 3-4 times daily for 8-12 weeks as a community-reported approach, though the source notes this route has poor bioavailability (~2%).
Unverified imported account — SR-9009 Protocol Guide
An imported authored paraphrase, not a quotation or a recommended protocol.
Review: unverified historical account. The imported wording is preserved for attribution; its full clinical, dosing, efficacy or consensus claims have not been independently established. Unvalidated source account; no validated human dosing population or animal-to-human equivalence is inferred.
Imported wording: A sublingual administration pattern shared on Path To Peptides involves 10-20 mg held under the tongue 3 times daily, split across 8-12 week cycles.
Unverified imported account — SR-9009 Protocol Guide
An imported authored paraphrase, not a quotation or a recommended protocol.
Review: unverified historical account. The imported wording is preserved for attribution; its full clinical, dosing, efficacy or consensus claims have not been independently established. Unvalidated source account; no validated human dosing population or animal-to-human equivalence is inferred.
Imported wording: An injectable protocol described on Path To Peptides details 10 mg administered subcutaneously twice daily across 8-12 week cycles.
Pharmacokinetic context
No half-life recorded in this source snapshot. No value has been inferred.
Source references
Snapshot provenance
Source ID: catalog:hormone:sr9009. Commit: adc7684614f9439b41d91a3312b62e7982c7e20e. Review state: historical-not-reverified. Authored links are retained separately from the canonical evidence links in the public data. App templates/defaults and rejected drafts are archived, not deployed.
Related entries and components
None listed.